METASTATIC
Clinical trials for METASTATIC explained in plain language.
Never miss a new study
Get alerted when new METASTATIC trials appear
Sign up with your email to follow new studies for METASTATIC, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Smart immune cells take aim at Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new approach using a patient's own immune cells, engineered to attack two cancer targets at once, for adults with advanced solid tumors that have not responded to standard treatments. Each participant's cancer is first tested to find the best two targets, then …
Matched conditions: METASTATIC
Phase: PHASE1, PHASE2 • Sponsor: Beijing Biotech • Aim: Disease control
Last updated May 26, 2026 05:49 UTC
-
New drug duo aims to control tough lung cancer
Disease control Recruiting nowThis study tests the safety and effectiveness of combining two drugs, lorlatinib and ramucirumab, for people with advanced ALK-rearranged non-small cell lung cancer. About 56 participants will receive different doses to find the best one with the fewest side effects. The goal is …
Matched conditions: METASTATIC
Phase: PHASE1, PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated May 26, 2026 04:37 UTC
-
New combo aims to wipe out hidden breast cancer cells
Disease control Recruiting nowThis study tests whether adding sarilumab to standard chemotherapy can clear leftover cancer cells in people with triple negative breast cancer, a fast-growing type. The trial has two parts: first, finding the safest dose in people with advanced cancer; second, testing that dose …
Matched conditions: METASTATIC
Phase: PHASE1, PHASE2 • Sponsor: University of Southern California • Aim: Disease control
Last updated May 22, 2026 14:04 UTC
-
New hope for rare gut cancers: drug combo shows promise in early trial
Disease control Recruiting nowThis study tests a combination of three drugs (surufatinib, sintilimab, and capecitabine) in people with advanced small bowel or appendix cancer that has spread and not responded to prior treatment. The goal is to see if this combination can shrink tumors or slow cancer growth. A…
Matched conditions: METASTATIC
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated May 14, 2026 12:06 UTC